Immunosuppression minimization

Preclinical

Immunosuppression minimization is one of 6 therapeutic programs targeting Liver Transplantation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Liver TransplantationEnrolling by invitation

Liver TransplantationPreclinical

Enrolling by invitation

Competition

Competitive Landscape

5 competitors in Liver Transplantation

#DrugCompanyPhaseTrials

Dolophine

HHikma Pharmaceuticals LLC

Approved

1 2

Ketalar

AAultman Health Foundation

Approved

1 3

Dilaudid

RRhodes Pharmaceuticals, L.P.

Approved

1 4

Duragesic

CCephalon

Approved

1 5

Immunosuppression minimization

CChang Gung Memorial Hospital

Preclinical

1 6

Immunosuppression Withdrawal

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Liver Transplantation1 trial

The Investigation of Transplant Tolerance and Immunosuppressant Withdrawal Based on Parenchymal Chimerism in the Liver

Enrolling by invitation·CChang Gung Memorial Hospital·Preclinical·NCT07735650·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Immunosuppression minimization. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Immunosuppression minimization. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Chang Gung Memorial Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: CChang Gung Memorial Hospital

Immunosuppression minimization

Status by Indication[2][1]

Competitive Landscape

Trials by Indication[1]

Liver Transplantation1 trial

References

Drug Info

Quick Facts

Related News